{
  "docId": "019de076-91e2-76fd-b3d2-f30dde172711",
  "docSlug": "0239a71f9c69421092604a0a694fdb09",
  "documentTitle": "AstraZeneca | Investor Conference Presentation Deck | 26 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 26,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide highlights both internal R&D focus areas and external acquisitions (Cellectis, Quell, Gracell) to support long-term growth.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-91e2-76fd-b3d2-f30dde172711/19",
  "deckHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711",
  "deckJsonHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711.json",
  "deckAnchorHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.85
      },
      "kind": "callout",
      "text": "Investment in novel technologies across next-wave pipeline support continued disease area leadership",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "440e09ce-6213-467a-99f4-9fdf4a42ac43",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.18,
        "y": 0.25
      },
      "kind": "image",
      "text": "Pipeline technology icons",
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea33424c-bf1e-4ab9-8075-bb86e3933816",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "image",
      "text": "Cellectis, Quell, Gracell logos",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c35743c7-0cdc-4ffa-80c2-8b5e7dfddbe9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.03,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "1. Gracell acquisition remains subject to customary closing conditions; all clinical development plans mentioned herein subject to deal closure. Collaboration partners: Compugen (rilvegostomig), Eccogene (AZD5004).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "068b9352-c245-4c3a-bb11-c6ffe886eb20",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.52,
        "y": 0.35
      },
      "kind": "table",
      "text": "Upcoming data readouts by drug and timeline",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aea7e7e6-a649-4b27-9853-3722941353bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Accelerating our next-wave pipeline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23cf17e5-0990-4cb2-99f3-36f76b7dd83c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Supporting our ambition for long-term industry-leading growth",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d51b421-637e-470d-831c-68ccc40e8ac2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "roadmap",
      "slug": null,
      "matchId": "a972a17b-0164-42a5-bf0a-935bd7496075",
      "evidence": "Timeline of upcoming data readouts",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 21,
      "from": 18,
      "beatId": "3cef57b3-4ceb-43aa-be90-d631b3225e75",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Ultimate Achievement",
      "beatSlug": "rags-to-riches-ultimate-achievement",
      "evidence": "The deck concludes with a strong call to action, emphasizing AstraZeneca's unique investment opportunity.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}